Merus (MRUS)
(Delayed Data from NSDQ)
$50.01 USD
+1.01 (2.06%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $50.02 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRUS 50.01 +1.01(2.06%)
Will MRUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRUS
Should You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings?
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
MRUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
Other News for MRUS
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS), Twist Bioscience (TWST) and Owens & Minor (OMI)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (PNTG), Merus (MRUS) and Sangamo Biosciences (SGMO)
Merus to Present at Canaccord Genuity?s 44th Annual Growth Conference
3 Best Stocks to Buy Now, 8/5/2024, According to Top Analysts
Buy Rating Affirmed for Merus on Strong Clinical Progress and Capital Raise